A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...

The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...

PROTECT H2H is the first randomized IDE trial of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints, representing a significant clinical and regulator ...

Emboline's Emboliner system excels in a global trial, showing superior debris capture and procedural success in TAVR patients ...

In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US ...

Lawrenceville, Ga.-based Northside Hospital Gwinnett is the first hospital in Georgia, and the first in the U.S. outside a clinical trial, to use Emboline’s embolic protection catheter during a ...

Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. We could see the ...

Fluidx Medical Technology, Inc. announced that the first patient has been treated with the company’s Ultra embolic gel in a ...

AMSTERDAM--(BUSINESS WIRE)--Assurant, Inc. (NYSE: AIZ), a premier global protection company that safeguards and services connected devices, homes and automobiles in partnership with the world’s ...